Adult T-Cell Leukemia/Lymphoma
Relapsed/Refractory
The term “relapsed” refers to disease that reappears or grows again after a period of remission. The term “refractory” is used to describe when the lymphoma does not respond to treatment (meaning that the cancer cells continue to grow) or when the response to treatment does not last very long.
Similar to the first-line setting, standard treatment for relapsed/refractory ATLL has not been established. Many chemotherapy regimens used to treat other T-cell lymphomas following a relapse are also being used to treat ALL, including the following:
- DHAP (dexamethasone, cytarabine, and cisplatin)
- ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin)
- GDP (gemcitabine, dexamethasone, and cisplatin)
- ICE (ifosfamide, carboplatin, and etoposide)
- Pralatrexate (Folotyn)
- Belinostat (Beleodaq).
Learn More
To learn more about ATLL, download the T-Cell Lymphomas Guide Want to talk to someone? For answers to lymphoma-related questions and resources, contact our Lymphoma Resource Center at (800) 500-9976 or [email protected].
Additional Resources
To learn more about ATLL, view the T-Cell Lymphomas Guide.
Events
Events
-
-
Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease
Ask the Doctor About Lymphoma is a virtual two-hour program that combines a comprehensive and […]
-
Understanding and Accessing Chimeric Antigen Receptor (CAR) T-Cell Therapy Webinar
Webinars are hour-long interactive programs discussing the diagnosis and treatment of specific lymphoma subtypes and […]
-
-
Supporting a Loved One with Lymphoma: A Webinar for Care Partners
Program Overview This program is hosted virtually on Zoom and can be accessed online and […]